Antihypertensive Medication Selection in Solitary Kidney
In a patient with a solitary kidney, blood pressure control should be prioritized because hypertension can damage the remaining kidney and accelerate kidney failure risk. [1] Angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are appropriate kidney-protective antihypertensive options in this setting. [1]
Core Recommendation for Medication Choice
Renin-angiotensin system inhibitors (RAS inhibitors) should be used in patients with high blood pressure and chronic kidney disease (CKD) when albuminuria is present, including moderately to severely increased albuminuria. [2] RAS inhibitors include ACE inhibitors and ARBs. [2]
Medication Selection Algorithm
First-line classes for patients with high blood pressure and CKD include the following. [2]
- RAS inhibitors (ACE inhibitors such as lisinopril or enalapril, and ARBs such as losartan or valsartan). [2]
- Calcium channel blockers (CCBs) (including non-dihydropyridine CCBs such as diltiazem and verapamil). [2]
- Thiazide-like diuretics (including chlorthalidone and indapamide). [2]
When a 3-drug combination is needed for BP control, common foundational combinations include RAS inhibitor plus CCB plus diuretic, at recommended doses. [2]
Monotherapy Versus Combination Therapy
RAS inhibitors should be initiated in appropriate CKD patients with high blood pressure and albuminuria. [2] If blood pressure control is not achieved with an initial regimen, additional therapy should be added using evidence-supported antihypertensive classes used in CKD (including combinations built from RAS inhibitor, CCB, and thiazide-like or other diuretics). [2]
Initiation Thresholds and Treatment Indications
Pharmacologic antihypertensive therapy should be initiated for adults with average blood pressure ≥140/90 mm Hg in addition to lifestyle interventions. [3] Pharmacologic therapy should also be initiated for selected adults with average blood pressure ≥130/80 mm Hg who have chronic kidney disease. [3]
Targets for Blood Pressure Reduction
KDIGO BP targets in CKD should be used as follows.
- Target systolic blood pressure (SBP) <120 mm Hg when tolerated using standardized office BP measurement. [2] AHA/ACC guidance for patients with CKD supports BP goals that incorporate kidney disease comorbidity and emphasizes intensive SBP lowering with careful balancing of benefits and adverse events. [3]
Monitoring and Dose-Adjustment Principles
After initiation or dose increase of a RAS inhibitor, serum creatinine and serum potassium should be checked within 2–4 weeks based on GFR and serum potassium status. [2] ACE inhibitor or ARB therapy should be continued unless serum creatinine rises by more than 30% within 4 weeks after initiation or dose increase. [2]
Common Pitfalls to Avoid
ACE inhibitor and ARB therapy should be avoided or used with heightened caution in settings where the patient is at high risk for acute kidney injury or hyperkalemia, including volume depletion or renal artery stenosis, due to the risk of AKI and hyperkalemia associated with RAS inhibitors. [2]
Solitary Kidney–Specific Practical Considerations
The solitary kidney condition requires monitoring of kidney function and urine albumin and requires monitoring and control of blood pressure. [1] ACE inhibitors and ARBs are specifically identified as potentially effective options for slowing kidney disease progression while lowering blood pressure in solitary kidney patients with hypertension. [1] A diuretic may also be prescribed for blood pressure lowering in solitary kidney patients diagnosed with high blood pressure. [1]